Galantamine Hydrobromide Solution
Product Images NDC 0054-0137

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Galantamine Hydrobromide (NDC 0054-0137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle.jpg (Bottle)

This text provides information about dispensing and storing a medication called Galantamine Oral Solution USP, which contains 4mg of galantamine hydrobromide per 1 mL of aqueous solution. Instructions for proper usage of the container and dispensing-syringe can be found in the accompanying Patient Instructions. The Package Insert should be consulted for complete prescribing information and usual dosage. The solution should be stored at 20°C to 25°C, and not frozen. This medication is distributed by West-Ward Pharmaceuticals Corp. and comes in a 100 mL bottle. The NDC number for this medication is 0054-0137-49. Keep this drug and all others out of the reach of children.*

FDA Label Image

Chem.jpg (Chem)

FDA Label Image

Figure-1.jpg (Figure 1)

FDA Label Image

Gal-figure-1-01.jpg (Gal Figure 1 01)

This appears to be a table or chart with scattered numbers and symbols. It is not clear what this table represents, as the headings or context are missing. Therefore, the description cannot be generated.*

FDA Label Image

Gal-figure-10-01.jpg (Gal Figure 10 01)

The text seems to indicate a dosage of 24mg/day and a placebo in a study that lasted for four weeks. The remaining text is not readable and appears to be a mix of characters and symbols.*

FDA Label Image

Gal-figure-11-01.jpg (Gal Figure 11 01)

FDA Label Image

Gal-figure-12-01.jpg (Gal Figure 12 01)

FDA Label Image

Gal-figure-2-01.jpg (Gal Figure 2 01)

FDA Label Image

Gal-figure-3-01.jpg (Gal Figure 3 01)

This is a table that shows the percentage of patients who experienced improvement or worsening of CIBIC-plus rating (a measure of cognitive and functional ability) in relation to different doses of a medication and a placebo. The percentage ranges from 50 to 10, with 50 representing the highest percentage of patients who experienced improvement. The medication was given at 8mg/day, 16mg/day, and 24mg/day respectively. The table also shows the degree of improvement and worsening experienced by the patients.*

FDA Label Image

Gal-figure-4-01.jpg (Gal Figure 4 01)

This text seems to describe a clinical trial involving a medication called Placebo. The medication is administered at two different dosages, 24mg/day and 32mg/day. The rest of the text seems to be gibberish, likely due to errors in .*

FDA Label Image

Gal-figure-5-01.jpg (Gal Figure 5 01)

The text provides a graph showing the cumulative percentage of patients with ADAS-cog change from baseline. The graph also shows three points (-10 points, -7 points, and -4 points) where the score worsens. There is a "No Change" category listed as well. The graph compares the effects of placebo with two doses of medication (24 mg/day and 32 mg/day) on ADAS-cog change.*

FDA Label Image

Gal-figure-6-01.jpg (Gal Figure 6 01)

FDA Label Image

Gal-figure-7-01.jpg (Gal Figure 7 01)

This appears to be a chart displaying dosages of a medication administered over a period of 13 weeks. The medication appears to have two different dosages, 32 mg/day and 24 mg/day, with a placebo also included. The remaining characters, including special characters such as "¥" and "—", do not provide any additional useful information.*

FDA Label Image

Gal-figure-8-01.jpg (Gal Figure 8 01)

The given text seems to represent a graph that shows the cumulative percentage of patients with different scores. The scores are marked on the X-axis, such as -10 points, -7 points, -4 points, and no change. Three treatments are compared with each other, which are represented by different lines with labels of Placebo, 24 mg/day, and 32 mg/day. The Y-axis shows the cumulative percentage of patients. The graph also shows the ADAS-cog change from the baseline.*

FDA Label Image

Gal-figure-9-01.jpg (Gal Figure 9 01)

This appears to be a chart displaying the percentage of patients who showed various levels of improvement after taking different doses of a medication. The medication is not specified and there is not enough context to accurately interpret the chart.*

FDA Label Image

Patient-gal-figure2.jpg (Patient Gal Figure2)

FDA Label Image

Patient-gal-figure3a-2.jpg (Patient Gal Figure3a 2)

FDA Label Image

Patient-gal-figure3b.jpg (Patient Gal Figure3b)

FDA Label Image

Patient-gal-figure4a-2.jpg (Patient Gal Figure4a 2)

FDA Label Image

Patient-gal-figure4b.jpg (Patient Gal Figure4b)

FDA Label Image

Patient-gal-figure5a-2.jpg (Patient Gal Figure5a 2)

FDA Label Image

Patient-gal-figure5b-2.jpg (Patient Gal Figure5b 2)

FDA Label Image

Patient-gal-figure6-2.jpg (Patient Gal Figure6 2)

FDA Label Image

Patient-gal-figure7.jpg (Patient Gal Figure7)

FDA Label Image

Patient-gal-figure8a-2.jpg (Patient Gal Figure8a 2)

FDA Label Image

Patient-gal-figure8b-2.jpg (Patient Gal Figure8b 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.